BioCorRx (BICX) Cash from Financing Activities (2016 - 2025)
BioCorRx (BICX) has disclosed Cash from Financing Activities for 16 consecutive years, with $699394.0 as the latest value for Q4 2025.
- Quarterly Cash from Financing Activities rose 108.7% to $699394.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 109.96% year-over-year, with the annual reading at $2.3 million for FY2025, 109.96% up from the prior year.
- Cash from Financing Activities hit $699394.0 in Q4 2025 for BioCorRx, down from $810263.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.2 million in Q1 2021 to a low of $59158.0 in Q2 2024.
- Historically, Cash from Financing Activities has averaged $548661.2 across 5 years, with a median of $442649.0 in 2023.
- Biggest five-year swings in Cash from Financing Activities: soared 842.13% in 2021 and later crashed 89.53% in 2024.
- Year by year, Cash from Financing Activities stood at $700000.0 in 2021, then crashed by 35.05% to $454662.0 in 2022, then fell by 2.64% to $442649.0 in 2023, then fell by 24.29% to $335113.0 in 2024, then skyrocketed by 108.7% to $699394.0 in 2025.
- Business Quant data shows Cash from Financing Activities for BICX at $699394.0 in Q4 2025, $810263.0 in Q3 2025, and $214229.0 in Q2 2025.